

**Bijuva (estradiol and progesterone)
Effective 12/1/2019**

Plan	<input checked="" type="checkbox"/> MassHealth <input checked="" type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit (NLX)		
Specialty Limitations	N/A		
Contact Information	Specialty Medications		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	Non-Specialty Medications		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	Medical Specialty Medications (NLX)		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
Exceptions	N/A		

Overview

Bijuva is a combination product containing estradiol and progesterone FDA approved for the treatment of moderate to severe vasomotor symptoms due to menopause.

Coverage Guidelines

Authorization may be granted for members who are currently receiving treatment with Bijuva, excluding when the product is obtained as samples or via manufacturer’s patient assistance programs

OR

Authorization may be granted if the member meets all following criteria and documentation has been submitted:

1. Member is at least 18 years of age
2. Member has diagnosis of moderate to severe vasomotor symptoms due to menopause
3. Member has had an inadequate response, intolerance or a contraindication to an estrogen and progesterone formulation taken concurrently as separate agents

Limitations

1. Approvals will be granted for 12 months

References

1. Bijuva (estradiol and progesterone) [prescribing information]. Boca Raton, FL: Therapeutics MD, Inc; March 2019
2. Cobin RH, Goodman NF; AACE Reproductive Endocrinology Scientific Committee. American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) position statement on menopause-2017 update. *Endocr Pract.* 2017;23(7):869-880. doi: 10.4158/EP171828.PS



3. Simon JA, Kaunitz AM, Kroll R, Graham S, Bernick B, Mirkin S. Oral 17 β -estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms. *Menopause*. 2018. doi: 10.1097/GME.0000000000001271

Review History

09/18/19 – Reviewed

Disclaimer

AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.